TLR4 Agonist GLA-SE

DRUG2 trials

Conditions

Stage IIA Skin MelanomaStage IIB Skin MelanomaStage IIC Skin MelanomaStage III Adult Soft Tissue SarcomaStage IIIA Skin MelanomaStage IIIB Skin MelanomaStage IIIC Skin MelanomaStage IV Adult Soft Tissue Sarcoma

Early Phase 1

MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

CompletedNCT02320305

Mayo ClinicStage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma +4

Start: 2015-01-27End: 2019-04-11Updated: 2020-01-14

Phase 1

TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery

CompletedNCT02180698

Fred Hutchinson Cancer CenterStage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma

Start: 2014-11-17End: 2016-10-07Updated: 2019-11-06

JAMA Oncology2023-10-1225 citations

Peptide Vaccine with Glucopyranosyl Lipid A–Stable Oil-in-Water Emulsion for Patients with Resected Melanoma

Immunotherapy2020-08-058 citations

Effect of intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 on a clinical response and CD4 T-cell response locally and systemically.

Journal of Clinical Oncology2018-02-104 citations

Using G100 (Glucopyranosyl Lipid A) to transform the sarcoma tumor immune microenvironment.

Journal of Clinical Oncology2016-05-202 citations

TLR4 Agonist GLA-SE

Sponsors

Conditions

Early Phase 1

Phase 1

Related Papers